共 50 条
- [32] Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2014, 18 (06): : 419 - 424
- [34] Febrile neutropenia prophylaxis with short- and long-acting granulocyte colony-stimulating factors during treatment of solid tumours ONCOLOGY IN CLINICAL PRACTICE, 2020, 16 (01): : 9 - 13
- [35] Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer Supportive Care in Cancer, 2023, 31
- [37] Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients European Journal of Clinical Pharmacology, 2018, 74 : 315 - 321
- [39] Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer Supportive Care in Cancer, 2021, 29 : 3507 - 3512